Publications by authors named "Katherine Liming"
Article Synopsis
- Selpercatinib is a RET inhibitor used to treat specific types of cancers, and a long-term safety analysis showed that most side effects can be managed with dose changes.
- The study included 837 patients with RET fusion-positive tumors, who were followed for an average of 45.4 months, revealing high rates of grade ≥3 adverse effects, primarily hypertension and elevated liver enzymes.
- Despite significant side effects, most patients were able to continue treatment, indicating that long-term use of selpercatinib is possible with appropriate management of adverse events.
